← All Zevra Therapeutics, INC filings

Zevra Therapeutics, INC 8-K filings

NASDAQ
ZVRA
Zevra Therapeutics, INC
8-K: Zevra Therapeutics Announces FDA Extends Review Period for Arimoclomol NDA, New PDUFA Date Set
The FDA has extended the review period for Zevra Therapeutics' arimoclomol NDA, setting a new PDUFA action date of September 21, 2024.
NASDAQ
ZVRA
Zevra Therapeutics, INC
8-K: Zevra Therapeutics Updates Bylaws to Align with SEC Universal Proxy Rules
Zevra Therapeutics has amended and restated its bylaws to incorporate universal proxy rules and update stockholder nomination procedures, effective February 22, 2024.
NASDAQ
ZVRA
Zevra Therapeutics, INC
8-K/A: Zevra Therapeutics Completes Acquisition of Acer Therapeutics, Files Amended 8-K
Zevra Therapeutics has filed an amended 8-K report to include the financial statements and pro forma information related to its acquisition of Acer Therapeutics, which was completed on November 20, 2023.
NASDAQ
ZVRA
Zevra Therapeutics, INC
8-K: Zevra Therapeutics Appoints Dr. Alvin Shih to Board of Directors
Zevra Therapeutics has appointed Dr. Alvin Shih, a seasoned biotech executive with extensive experience in rare diseases, to its board of directors, effective immediately.